- Funding Opportunities
- The NCI Grants Process
- Application and Forms
- NCI Sponsored Research Initiatives
- Policies and Guidelines
- Grants and Contracts
- Cancer Research Training
- Advisory Boards
- President's Cancer Panel
- National Cancer Advisory Board
- Board of Scientific Advisors
- Board of Scientific Counselors - Basic Sciences
- Board of Scientific Counselors - Clinical Sciences and Epidemiology
- Clinical Trials and Translational Research Advisory Committee
- NCI Council of Research Advocates
- Frederick National Laboratory Advisory Committee
- NCI Initial Review Groups
- Special Emphasis Panel
- Office of Federal Advisory Committee Policy
- Board Presentations
- Grant Policies
- Consumer Advocates
- NCI Consumer Guide to Peer Review
The NCI Consumer Guide to Peer Review has been prepared to serve first as an introduction and orientation to the National Cancer Institute (NCI) and its Research Programs and second to define your role as a consumer in the Peer Review of applications that support extramural clinical/population-based research conducted by Cancer Centers, Cooperative Groups, Program Projects, and projects submitted in response to Requests for Applications (RFAs) and Program Announcements (PAs).
- Cancer Dictionary for Peer Review
Cancer Dictionary for Peer Review is deigned to provide concise definitions of technical terms frequently used in applications for NCI-sponsored investigator-initiated research. The terms include those commonly associated with the molecular biology of cancer, immunology, and clinical oncology. These definitions, in association with the review process, will increase your familiarity and understanding of the biology and clinical aspects of cancer. We hope this will facilitate and make your participation in the Peer Review process more meaningful.
- Office of Advocacy Relations
- NCI Council of Research Advocates
- NCI Consumer Guide to Peer Review
- Awarded Research
The National Cancer Institute conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. For more information or to view the Institute's mission statement, please go to the NCI website: https://www.cancer.gov/aboutnci.
Information on the FY 2020 budget can be found on the NCI Office of Budget and Finance website: https://www.cancer.gov/about-nci/budget.
In FY 2020 peer review evaluation of scientific merit will remain the primary consideration in NCI funding decisions, which will be made by NCI Scientific Program Leaders (SPL) following discussions with program staff. The NCI will also continue its efforts to support early career investigators and give special consideration to applications that fill a significant gap in the cancer research portfolio or propose an especially novel or promising scientific approach.
NCI will generally fund both categorical and modular non-competing grants at 100% of the committed levels. Non-competing grants that were awarded under the continuing resolution policy will be revised accordingly.
Traditional Research Grants - Experienced and New Investigator (R01) & Exploratory Development Grants (R21s)
Most Traditional (R01) Experienced and New Investigator applications with scores up to and including the 10th percentile and Exploratory Development (R21) applications with scores up to and including the 9th percentile will be funded without additional review. Applications with higher scores require NCI division and Scientific Program Leader (SPL) review before final funding decisions are made. Information on the outcomes of grant selections from recent years can be viewed at: Awards of R01 and R21 Grants in FY 2018.
Early State Investigators (ESIs)
NCI is strongly committed to supporting early stage investigators (ESIs) and will place special emphasis on supporting these applicants. Most Traditional R01 selections submitted by ESIs with scores up to the 15th percentile will be funded without additional review by the NCI Scientific Program Leaders (SPL). Applications that are within the regular R01 payline (10th percentile) may be eligible for conversion to an R37 Method to Extend Research In Time (MERIT) award if all PIs are ESIs at the time of award Merit R37 Conversion notice.
Current definitions and additional information regarding New and Early Stage Investigators can be found on the NIH's Office of Extramural Research website at: New Stage and Early Established Investigator Policies.
Program Projects (P01s)
All P01 applications will be individually reviewed for funding selection by the NCI Scientific Program Leaders (SPL).
Outstanding Investivator Awards (R35)
All R35 applications will be individually reviewed for funding selection by the NCI Scientific Program Leaders (SPL). There will be no funding policy reductions applied to these grants.
Small Grants (R03s) & AREA Grants (R15)
Small (R03) and AREA (R15) grant applications with scores up to and including 25 will likely be funded with no policy reductions. Applications with higher scores may be individually selected for funding depending on the availability of funds.
Large Dollar Amount R01s ($700,000 or more in direct cost requested in any year)
All Large R01s will be individually reviewed for funding selection by the NCI Scientific Program Leaders (SPL).
Request for Applications (RFA)
RFA applications are considered for funding by the NCI Scientific Program Leaders (SPL). Success rates for RFAs will depend on the scientific merit and programmatic priority of each application, the number of applications submitted, and the amount of funds available. NCI does not consider it obligatory to use all funds set aside for any RFA. Please contact the program director listed on your summary statement if you have questions.
Competing RPG Funding Policy Reductions
R01 & U01 Modular Applications: Competing renewals (Type-2s) will generally be funded at 5% below the allowable requested level 1. New Modular (R01) applications (Type-1s) with a direct cost $175,000 or less will generally be funded at a 6.5% reduction from the Initial Review Group (IRG) recommended level. New Modular (R01) applications (Type 1s) with a direct cost over $175,000 will generally be funded at an 8.5% reduction. Foreign applications with direct costs under $250,000 will be treated as modular grants in applying funding policy reductions.
R01 & U01 Categorical (Non-modular) Applications: Competing renewals (Type-2s) will generally be funded at 10% below the allowable requested level1. New Categorical Traditional (R01) grants (Type-1s) will generally be funded at a 17% reduction from the Initial Review Group (IRG) recommended level.
R21 Applications: New applications (Type-1s) with a direct cost $175,000 or less will generally be funded at a 6.5% reduction from the Initial Review Group (IRG) recommended level. New applications (Type 1s) with a direct cost over $175,000 will generally be funded at an 8.5% reduction..
Other RPG Reductions (P01, UM1, R33): Competing renewals (Type-2s) will generally be funded at 10% below the allowable requested level 1. New (Type-1) applications requesting $175,000 or less will generally be funded at a 13% reduction from the Initial Review Group (IRG) recommended level, and those requesting over $175,000 in direct costs will generally be funded at a 17% reduction.
No Policy Reduction: No funding policy reductions will be applied to the following grant awards:
- Outstanding Investigator (R35)
- Small Grant (R03)
- Academic Research Enhancement Award (R15)
- Research Specialist Award (R50)
- Small Business Innovation Research (R43/R44)
- Small Business Technology Transfer (R41/R42)
1 The allowable requested level is the amount that the PI is allowed to request for a competitive renewal (Type-2). For FY 2020 this amount is generally 10% over the final year commitment on the most recent competing award.